<DOC>
	<DOCNO>NCT02126462</DOCNO>
	<brief_summary>Na-GST-1 Na-APR-1 protein express adult stage Necator americanus hookworm life cycle think play role parasite 's degradation host hemoglobin use energy source . Vaccination recombinant GST-1 APR-1 protect dog hamster infection challenge study . This study evaluate safety immunogenicity co-administering Na-GST-1 Na-APR-1 healthy Gabonese adult live area endemic hookworm infection .</brief_summary>
	<brief_title>Safety Immunogenicity Co-Administered Hookworm Vaccine Candidates Na-GST-1 Na-APR-1 Gabonese Adults</brief_title>
	<detailed_description>Double-blind , randomize , control dose-escalation Phase 1 clinical trial hookworm expose adult . Study site : Centre de Recherches Médicales de Lambaréné Number participant : 32 2 cohort 16 Doses Na-GST-1 test : 30 100 μg Doses Na-APR-1 test : 30 100 μg Dose GLA-AF : 5 μg per antigen Cohort 1 : 30 μg two antigen ( Na-GST-1/Alhydrogel® Na-APR-1 ( M74 ) /Alhydrogel® ) hepatitis B vaccine ; Cohort 2 : 100 μg two antigen ( Na-GST- 1/Alhydrogel® Na-APR-1 ( M74 ) /Alhydrogel® ) hepatitis B vaccine . Randomization : Cohort 1 : 30 μg Na-GST-1 + 30 μg Na-APR-1 ( M74 ) ( n = 12 ) versus Hepatitis B Vaccine/placebo ( n = 4 ) Cohort 2 : 100 μg Na-GST-1 + 100 μg Na-APR-1 ( M74 ) ( n = 12 ) versus Hepatitis B Vaccine + placebo ( n = 4 ) The cohort enrol staggered fashion safety data assess prior Na-GST-1 Na-APR-1 dose escalation 30 100 µg . Pre-treatment : Albendazole ( 400 mg ) least 2 week prior first vaccination Immunization schedule : Study day 0 , 28 180 Route : Intramuscular deltoid muscle Study duration : approximately 20 month ; participant follow total 12 month .</detailed_description>
	<mesh_term>Hookworm Infections</mesh_term>
	<mesh_term>Ancylostomiasis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Aluminum Hydroxide</mesh_term>
	<criteria>Males females 18 50 year , inclusive , longterm resident Gabon . Good general health determine mean screening procedure . Assumed availability duration trial ( 12 month ) . Willingness participate study evidence sign informed consent document . Negative hookworm screening , find infected hookworm , complete course three dos albendazole . Pregnancy determine positive urine hCG ( female ) . Participant unwilling use reliable contraception one month follow third immunization ( female surgically sterile , abstinent least 2 year postmenopausal ) . Currently lactate breastfeed ( female ) . Inability correctly answer question inform consent comprehension questionnaire . Evidence clinically significant neurologic , cardiac , pulmonary , hepatic , rheumatologic , autoimmune , diabetes , renal disease history , physical examination , and/or laboratory study . Known suspected immunodeficiency . Laboratory evidence liver disease ( alanine aminotransferase [ ALT ] great 1.25times upper reference limit ) . Laboratory evidence renal disease ( serum creatinine great 1.25times upper reference limit , trace protein blood urine dipstick test ) . Laboratory evidence hematologic disease ( absolute leukocyte count &lt; 3500/mm3 ; absolute leukocyte count &gt; 11.0 x 103/mm3 ; hemoglobin &lt; 10.000 g/dl [ female ] &lt; 12.0 g/dl [ male ] ; , platelet count &lt; 140,000/mm3 ) . Other condition opinion investigator would jeopardize safety right volunteer participate trial would render subject unable comply protocol . Participation another investigational vaccine drug trial within 30 day start study duration study . Volunteer medical , occupational , family problem result alcohol illicit drug use past 12 month . History severe allergic reaction anaphylaxis . Severe asthma define need daily use inhaler emergency room/clinic visit hospitalization within 6 month volunteer 's plan first vaccination study . Positive HCV Positive ELISA HBsAg . Positive HIV infection Use corticosteroid ( exclude topical nasal ) immunosuppressive drug within 30 day start study expect use duration study . Receipt live vaccine within past 4 week kill vaccine within past 2 week prior entry study . History surgical splenectomy . Receipt blood product within 6 month prior entry study . Previous receipt primary series hepatitis B vaccine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Human Hookworm</keyword>
	<keyword>Necator americanus</keyword>
	<keyword>Hookworm</keyword>
	<keyword>Hookworm Disease</keyword>
	<keyword>Iron-deficiency anemia</keyword>
	<keyword>Soil-transmitted helminth infection</keyword>
	<keyword>Neglected Tropical Disease</keyword>
	<keyword>Na-APR-1</keyword>
	<keyword>Na-GST-1</keyword>
</DOC>